ALTERITY THERAPEUTICS LTD (ATHE) Form 6-K — Aug 31, 2026

Alterity Therapeutics announced on August 31, 2026 that it filed its Annual Report on Form 20-F, containing audited consolidated financial statements for the fiscal year ended June 30, 2026, with the SEC, along with XBRL interactive data. The 6-K itself is administrative and discloses no new financial figures or clinical results. Alterity is a clinical-stage biotechnology company developing disease-modifying therapies for neurodegenerative diseases, focused on Multiple System Atrophy (MSA) and related Parkinsonian disorders.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.